Home › Acute Myeloid Leukemia › New Hampshire
Acute Myeloid Leukemia clinical trials in New Hampshire
9 studies for Acute Myeloid Leukemia are looking for participants at sites in New Hampshire.
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 28, 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Dartmouth Hitchcock Medical Center, Lebanon
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06672146A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
RecruitingPhase 3
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Dana Farber/New Hampshire Oncology-Hematology, Londonderry
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 7, 2026 · NCT02269592From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.